Variability in clopidogrel pharmacokinetics among patients has been appreciated for years and this results in inconsistent effects on platelet inhibition and poor outcomes. Multiple strategies to personalize antiplatelet therapy intended to balance the risks and benefits of therapy have been tested. A recent systematic review and meta-analysis attempts to answer the question: Is a personalized approach worth it?

Guest Authors:  Kiana R. Green, PharmD and Augustus (Rob) Hough, PharmD, BCPS, BCCP

Music by Good Talk